Current market sentiment around GALT stock forecast leans neutral, as traders weigh pipeline updates against broader biotech index weakness. The short interest ratio has eased, signaling reduced bearish bets in recent weeks. It would appear that 9.4% of Galectin Therapeutics shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Richard Uihlein is currently the largest shareholder, with 16% of shares outstanding. 10x Capital Management, LLC is the second largest shareholder owning 9.4% of common stock, and The Vanguard Group, Inc. holds about 3.4% of the company stock. Additionally, the company's CEO Joel Lewis directly holds 1.4% of the total shares outstanding. Be the first to see our newest insights and key updates across all datasets Short-term GALT stock forecast scenarios model potential $0.15 gains if positive clinical data emerges, aligning with historical post-news rallies seen in biotech small caps.
